Skip to main content
Optipharm.CO.,LTD logo

Optipharm.CO.,LTD — Investor Relations & Filings

Ticker · 153710 ISIN · KR7153710009 KO Professional, scientific and technical activities
Open in API
Filings indexed 177 across all filing types
Latest filing 2023-03-27 Board/Management Inform…
Country KR South Korea
Listing KO 153710

About Optipharm.CO.,LTD

https://www.optipharm.co.kr

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the appointment of new outside directors following a general meeting. This falls under the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors.
2023-03-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the share transactions (purchases) made by a director (Kim Hyun-il) of Optipharm. This type of filing is specifically categorized as a Director's Dealing (insider trade) report.
2023-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from the company Optipharm. It provides a summary of the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and auditor information. While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report, rather than the full annual report document itself. Therefore, it fits the 'Audit Report / Information' (AR) category as it specifically reports on the audit results and opinion. FY 2022
2023-03-17 Korean
사업보고서 (2022.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 23rd fiscal year (2022) of Optipharm, submitted to the Financial Services Commission and the Korea Exchange. It contains comprehensive financial statements, management discussion and analysis, business overview, and corporate governance details. This is the standard annual regulatory filing for a Korean listed company, which corresponds to the 10-K category in the provided schema. FY 2022
2023-03-17 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Optipharm) announcing a significant change in financial structure (revenue or profit/loss change of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to report material financial changes before the final audit is completed. It does not constitute a full annual report or an earnings release, but rather a specific regulatory disclosure of financial variance. FY 2022
2023-03-10 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for the company 'Optipharm'. It details the date, location, agenda items (such as financial statement approval and director appointments), and specific details regarding the board candidates. This document serves as the official solicitation and notification to shareholders regarding the meeting, which falls under the category of Proxy Solicitation & Information Statement (PSI).
2023-03-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.